Lisa Su Says AI Chip Demand Could Top $500 Billion In Just A Few Years — Says US Must Rapidly Scale Manufacturing To Keep Up With Elon Musk, Sam Altman
Advanced Micro Devices Inc. (NASDAQ:AMD) CEO Lisa Su has projected explosive growth in AI chip demand while warning that the U.S. must rapidly expand its manufacturing capacity to stay ahead in the global AI arms race.
What Happened: Speaking at an AI policy summit hosted by the Hill & Valley Forum and the "All-In" podcast on Wednesday, Su said AI chip demand could soar to more than $500 billion within a couple of years, driven by surging infrastructure needs from companies like Elon Musk's xAI and Sam Altman's OpenAI.
"We're imagining that just the accelerator market—so the chips for these AI large computing systems—will be like over $500 billion in a couple of years," Su said, citing the need for rapid scaling in both chip design and manufacturing.
Trending: 7,000+ investors have joined Timeplast's mission to eliminate microplastics—
She stressed that meeting this demand would require scaling "the entire ecosystem," not just silicon production. "The U.S. is going to be a huge piece of it," she added, calling the Donald Trump administration's AI Action Plan "a really excellent blueprint" for supporting growth.
Su also predicted a "Cambrian explosion" of chip diversity, saying AI's spread across science, manufacturing, personal devices, and more will require various custom-designed chips beyond just GPUs.
"I am a believer in there will be diversity of chips," she said.
Why It's Important: On Wednesday, Trump unveiled a trio of executive orders as part of his 'AI Action Plan,' aiming to strengthen U.S. leadership in artificial intelligence.
The orders seek to fast-track data center permitting, launch an American AI Exports Program to promote U.S. AI technology globally, and ban the use of ideologically biased AI—such as systems promoting diversity, equity, and inclusion (DEI)—in federal agencies.
Trump's push to reshore manufacturing has prompted major companies to revamp their strategies and boost investments in the U.S.Earlier this year, Apple Inc. (NASDAQ:AAPL) announced a $500 billion investment to expand domestic manufacturing, while Nvidia Corporation (NASDAQ:NVDA) plans to produce AI servers worth up to $500 billion in the country.
Other tech giants, including Amazon.com, Inc. (NASDAQ:AMZN), Alphabet Inc. (NASDAQ:GOOG) (NASDAQ:GOOGL) and IBM (NYSE:IBM) have also unveiled significant U.S. investment initiatives in response to the policy shift.Read Next:
$100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation.
If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it?
Photo courtesy: jamesonwu1972 On Shutterstock.com
This article Lisa Su Says AI Chip Demand Could Top $500 Billion In Just A Few Years — Says US Must Rapidly Scale Manufacturing To Keep Up With Elon Musk, Sam Altman originally appeared on Benzinga.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial
We recently published . Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on Monday. Celcuity soared by 167 percent on Monday to close at $36.79 apiece as investors cheered positive results in its clinical trial for its breast cancer treatment candidate. In a statement on Monday, Celcuity Inc. (NASDAQ:CELC) said it achieved positive topline results from the phase 3 clinical study of gedatolisib combined with palbociclib and fulvestrant—an experimental treatment for adults with two kinds of breast cancer. Called the gedatolisib triple, the three-drug combination reduced risk progression and death by 76 percent as compared with taking fulvestrant alone. Meanwhile, its gedatolisib double, which combines gedatolisib and fulvestrant, lowered the risk of progression and death by 67 percent, also achieving primary endpoints. Celcuity Inc.'s (NASDAQ:CELC) clinical trial success bolsters its chances of filing an approval with the Food and Drug Administration by the fourth quarter of the year. Copyright: bialasiewicz / 123RF Stock Photo Following the results, Celcuity Inc. (NASDAQ:CELC) earned a whopping $60 price target from Leerink, a marked increase from the $28 target previously. It also maintained an 'outperform' rating on its stock. While we acknowledge the potential of CELC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
21 minutes ago
- Business Wire
AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate
SEATTLE & HEIDELBERG, Germany--(BUSINESS WIRE)-- AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO's Heidelberg facility. Valneva exclusively licensed the vaccine candidate from LimmaTech Biologics AG, which previously worked with AGC Biologics to establish GMP-compliant manufacturing and quality control of the vaccine's complex protein-polysaccharide conjugates for first-in-human studies. The objective of the new partnership with Valneva is to establish phase II supply relying on the ability of AGC Biologics' Heidelberg site to guide complex molecules through clinical stages. Valneva and LimmaTech announced the launch of a Phase 2 infant study in April, and a Phase 2b Human Challenge Study (CHIM) in November 2024. Shigellosis is the second leading cause of fatal diarrheal disease worldwide, strongly contributing to pediatric morbidity and mortality. It is estimated that up to 165 million infections are due to Shigella, of which 62.3 million occur in children younger than five years. Developing an effective vaccine to prevent this deadly disease is a public health imperative for many areas of the world. "Our site's unique ability to handle complex molecules and multi-valent assets can help this potentially life-saving program reach its next clinical milestone," said Dieter Kramer, Senior Vice President and General Manager, AGC Biologics Heidelberg. "We appreciate Valneva entrusting our team of experts with this challenge and are honored to contribute to efforts that aim to prevent millions of deadly infections in the future." AGC Biologics runs multiple cGMP microbial fermentation lines at its Heidelberg facility. The site has produced biologics products for 40 years. It offers developers freedom-to-operate strain development, proven experience with different bacterial and yeast systems, proprietary plasmid DNA (pDNA) and messenger RNA (mRNA) platforms, large-scale tanks for late-phase protein refolding, the ability to take on early-phase and fast track projects, and late-phase and commercial expertise. To learn more about the microbial system-based biologics, pDNA and mRNA manufacturing site in Heidelberg, visit For more information on AGC Biologics' global CDMO services across all modalities, go to About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit
Business Wire
21 minutes ago
- Business Wire
Paige and Oncoclínicas Strengthen Leadership in AI-Driven Cancer Diagnostics Across Brazil
NEW YORK & SíO PAULO--(BUSINESS WIRE)--Paige, a leader in next-generation AI technology, announced the continued and expanded use of its innovative AI-assisted diagnostic applications by long-time customer, Oncoclínicas&Co (Oncoclínicas), the largest private group of cancer care in Latin America. With a commitment to enhancing diagnostic capabilities and improving patient safety, Oncoclínicas has utilized Paige's technology across prostate and breast cancer diagnosis, supporting its commitment to advancing pathology standards throughout Brazil. Oncoclínicas employs a rigorous approach where all digitized prostate and breast cancer biopsy whole-slide images are analyzed by pathologists using AI as an adjunct diagnostic tool. This process provides extra layers of patient safety, enhancing both sensitivity and efficiency for the pathologists using the technology. Since August 2021, Oncoclínicas has utilized AI to support the review of over 23,000 prostate and breast biopsies. These results demonstrate the scale and commitment of Oncoclínicas to AI integration in their diagnostic workflow, which has led to Oncoclínicas' achieving: Faster second reader sign-out for senior pathologists using FullFocus™ and AI support. 1 Enhanced detection rates, including the identification of approximately .5% of precursor non-obligatory breast lesions that were not initially detected by pathologists. 1 Improved diagnostic consistency and efficiency through the use of Paige Prostate and Paige Breast AI Suites. 1 Dr. Leonard Medeiros da Silva, pathologist at OC Medicina de Precisão, an integrated laboratory of Oncoclínicas&Co dedicated to pathological anatomy, genetic testing and Big Data, reports a positive experience with Paige Prostate. "It aligns with Oncoclínicas published data showing nearly 100% sensitivity and 93% specificity,' he notes. 'The specialist also commends the technology's effectiveness in both cancer detection and accurate Gleason score determination.' 'We are proud to support Oncoclínicas in their mission to offer cutting-edge cancer diagnostic solutions,' said Dr. Juan Retamero, Medical Vice President at Paige. 'Their success in implementing AI technology is a testament to their dedication to clinical excellence and their forward-thinking approach to pathology. Our long-term partnership underscores Paige's commitment to providing access to high-quality AI technology globally, helping pathologists provide better diagnoses for their patients.' 'Over the past few months, I've had the opportunity to witness how the integration of digital pathology, biomarkers, AI, and genomics is accelerating the advancement of precision medicine, and, more importantly, improving patients' quality of life and offering new hope in the fight against cancer,' said Rodrigo Alvarenga, Operations Executive at Oncoclínicas&Co. 'At both the 2025 USCAP in Boston and ASCO in Chicago, it became clear that precision medicine is no longer a distant goal, but a present-day reality that can expand access to advanced technologies and enable more cost-effective care. We've reached an exciting point of no return, the convergence of AI, pathology, and genomics is not only transforming cancer care but is also critical to the long-term sustainability of our healthcare systems.' In Brazil, FullFocus™ and all AI assisted diagnostic applications such as the Paige Prostate Suite and the Paige Breast Suite are for Research Use Only. Not for use in diagnostic procedures. 1 Figures are based on independent clinical research conducted by Oncoclínicas&Co. Finding an average of 12,000 breast biopsies and surgical specimens were analyzed in 2024. The Paige Breast Suite as a second reader detected 55 non-obligatory precursor breast lesions that were not initially detected by pathologists. Additionally, after utilizing FullFocus™ with the Paige Prostate Suite, the average time to read a slide and complete a report reduced to one minute and 10 seconds. About Oncoclínicas&Co Oncoclínicas&Co is the largest group dedicated to cancer treatment in Latin America, with a highly specialized and innovative model focused on the oncology journey. With a medical staff of over 2,900 oncology specialists, the company operates in 40 Brazilian cities, totaling more than 140 units. Focused on research, technology, and innovation, the group has conducted approximately 682,000 treatments in the past 12 months. Oncoclínicas follows international standards of excellence, integrating outpatient clinics with high-complexity cancer centers, enhancing treatment through precision medicine and genomics. As the exclusive partner of the Dana-Farber Cancer Institute in Brazil, affiliated with Harvard Medical School, it has acquired Boston Lighthouse Innovation (USA) and holds a stake in MedSir (Spain). It is also part of the IDIVERSA index of B3, reinforcing its commitment to diversity. With the goal of expanding its global mission to overcome cancer, Oncoclínicas has entered Saudi Arabia through a joint venture with the Al Faisaliah Group, bringing its oncology expertise to a new continent. Learn more at: About Paige Paige is pushing the boundaries of AI to solve cancer's most critical issues, revolutionizing cancer care with next-generation technology. By leveraging exclusive access to millions of digitized pathology slides, clinical reports, and genomic data, Paige gains a holistic understanding of cancer, encompassing diverse factors such as gender, race, ethnicity, and geographical regions. This comprehensive data enables Paige to create advanced AI solutions that redefine cancer detection, diagnosis, and treatment. With a unique, intricate understanding of tissue, Paige sets new standards in precision diagnostics, earning the distinction of being the first FDA-cleared AI application in pathology. Paige has also developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products. For more information, visit
